Validation of nuclear receptor RORγ isoform 1 as a novel host-directed antiviral target based on the modulation of cholesterol levels (2024) Wangen C, Raithel A, Tillmanns J, Gege C, Herrmann A, Vitt D, Kohlhof H, et al. Journal article An antiviral targeting strategy based on the inducible interference with cytomegalovirus nuclear egress complex (2023) Kicuntod J, Häge S, Lösing J, Kopar S, Muller Y, Marschall M Journal article Target verification of artesunate-related antiviral drugs: Assessing the role of mitochondrial and regulatory proteins by click chemistry and fluorescence labeling (2020) Hahn F, Niesar A, Wangen C, Wild M, Grau B, Herrmann L, Capci A, et al. Journal article The trimeric artesunate derivative TF27 exerts strong anti-cytomegaloviral efficacy: Focus on prophylactic efficacy and oral treatment of immunocompetent mice (2020) Wild M, Bertzbach LD, Tannig P, Wangen C, Müller R, Herrmann L, Fröhlich T, et al. Journal article A highly potent trimeric derivative of artesunate shows promising treatment profiles in experimental models for congenital HCMV infection in vitro and ex vivo (2020) Jacquet C, Marschall M, Andouard D, El Hamel C, Chianea T, Tsogoeva S, Hantz S, Alain S Journal article Wedelolactone inhibits human cytomegalovirus replication by targeting distinct steps of the viral replication cycle (2020) Svrlanska A, Ruhland A, Marschall M, Reuter N, Stamminger T Journal article Artesunate derivative TF27 inhibits replication and pathogenesis of an oncogenic avian alphaherpesvirus (2019) Bertzbach LD, Conradie AM, Hahn F, Wild M, Marschall M, Kaufer BB Journal article Wedelolactone inhibits human cytomegalovirus replication by targeting distinct steps of the viral replication cycle (2019) Svrlanska A, Ruhland A, Marschall M, Reuter N, Stamminger T Journal article In vivo proof-of-concept for two experimental antiviral drugs, both directed to cellular targets, using a murine cytomegalovirus model (2019) Sonntag E, Hahn F, Bertzbach LD, Seyler L, Wangen C, Müller R, Tannig P, et al. Journal article Lipase inhibitor orlistat prevents hepatitis B virus infection by targeting an early step in the virus life cycle (2018) Esser K, Lucifora J, Wettengel J, Singethan K, Glinzer A, Zernecke A, Protzer U Journal article